Immunotherapy for untreated stage 3 lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an immunotherapy drug for people with stage 3 lung cancer that hasn't been treated yet. It's for those whose tumors don't have certain genetic changes and who have not had prior cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stage 3 non-small cell lung cancer that hasn't spread outside the chest and you haven't had chemotherapy or radiation yet.
- Your tumor does not have certain genetic changes (like EGFR, ALK, or ROS1) that can be treated with other drugs.
- You are in good enough health to be up and about (ECOG score 0 or 1) and expected to live at least 3 more months.
- You are willing to provide blood and tumor samples for research.
- You are not pregnant, breastfeeding, and agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies ivonescimab alone as a first treatment for people with advanced non-small cell lung cancer (NSCLC) that tests positive for PD-L1 and doesn't have certain gene changes. The goal is to see if it works and is safe in everyday medical practice.
This trial tests a combination of ivonescimab and docetaxel for people with advanced non-small cell lung cancer who have had a long response (11-15 months without the cancer getting worse) to first-line immunotherapy. The goal is to see if adjusting treatment based on ctDNA-MRD levels can improve outcomes.
This trial tests a combination of chemotherapy (platinum/etoposide) plus an immunotherapy drug (ivonescimab) for people with extensive-stage small cell lung cancer who have not received treatment before. The goal is to see if adding the immunotherapy improves outcomes.
This trial tests a new immunotherapy drug (ivonescimab) given before and after surgery, sometimes with chemotherapy, for people with operable non-small cell lung cancer. The goal is to see if it helps shrink tumors and keeps them from coming back.
This Phase 3 trial tests ivonescimab as a first-line treatment for metastatic non-small cell lung cancer (NSCLC). It may help people by improving how well the cancer responds, especially in tumors with PD-L1 activity, but you must meet specific medical and testing requirements.
This trial tests a new immunotherapy drug called ivonescimab combined with focused radiation therapy (SBRT) for patients with early-stage non-small cell lung cancer who cannot or prefer not to have surgery. The goal is to see if this combination can effectively treat the cancer while being tolerable.
Hear when a new Non-small Cell Lung Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.